Type I insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase that is involved in the transformation of cells, cancer proliferation, and metastatic events in various types of cancer. The present study reports on the generation of a mouse monoclonal antibody (MAb) to IGF-1R using the mouse lymph node method. MAb 1B1, which reacts specifically with the extracellular domain of IGF-1R, was obtained using flow cytometry (FCM) screening using MCF-7 cells. Using immunostaining, MAb 1B1 detected IGF-1R mainly on the plasma membrane of MCF-7 cells. MAb 1B1 would be useful in FCM and immunofluorescence assays to detect IGF-1R-expressing cells for basic and clinical research.
Get full access to this article
View all access options for this article.
References
1.
AdamsTE, EpaVC, GarrettTP, and WardCW: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci, 2000; 57:1050–1093.
2.
Germain-LeeEL, JanicotM, LammersR, UllrichA, and CasellaSJ: Expression of a type I insulin-like growth factor receptor with low affinity for insulin-like growth factor II. Biochem J, 1992; 281:413–417.
3.
ChitnisMM, YuenJS, ProtheroeAS, PollakM, and MacaulayVM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res, 2008; 14:6364–6370.
4.
CarboniJM, LeeAV, HadsellDL, RowleyBR, LeeFY, BolDK, CamusoAE, GottardisM, GreerAF, HoCP, HurlburtW, LiA, SaulnierM, VelaparthiU, WangC, WenML, WesthouseRA, WittmanM, ZimmermannK, RupnowBA, and WongTW: Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res, 2005; 65:3781–3787.
5.
GallagherEJ, and LeRoithD: The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab, 2010; 21:610–618.
6.
SachdevD, HartellJS, LeeAV, ZhangX, and YeeD: A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem, 2004; 279:5017–5024.
7.
ArcaroA: Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol, 2013; 4:30.
8.
GombosA, Metzger-FilhoO, Dal LagoL, and Awada-HusseinA: Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad?. Invest New Drugs, 2012; 30:2433–2442.
9.
OlmosD, Postel-VinayS, MolifeLR, OkunoSH, SchuetzeSM, PaccagnellaML, BatzelGN, YinD, Pritchard-JonesK, JudsonI, WordenFP, GualbertoA, ScurrM, de BonoJS, and HaluskaP: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol, 2010; 11:129–135.
10.
SoriaJC, MassardC, LazarV, OzouxML, Mery-MignardD, DeslandesA, and TolcherAW: A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer, 2013; 49:1799–1807.
11.
KingER, and WongKK: Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov, 2012; 7:14–30.
12.
ZhangH, SachdevD, WangC, HubelA, Gaillard-KellyM, and YeeD: Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat, 2009; 114:277–285.
13.
CalzoneFJ, CajulisE, ChungYA, TsaiMM, MitchellP, LuJ, ChenC, SunJ, RadinskyR, KendallR, and BeltranPJ: Epitope-specific mechanisms of IGF1R inhibition by ganitumab. PLoS One, 2013; 8:e55135.
